198 related articles for article (PubMed ID: 36468020)
21. Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.
Huang X; Wang HF; Huang S
Front Genet; 2022; 13():906880. PubMed ID: 36061188
[No Abstract] [Full Text] [Related]
22. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
23. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
24. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
25. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
[TBL] [Abstract][Full Text] [Related]
26. Bioinformatics analysis of prognosis and immune microenvironment of immunological cell death-related gemcitabine-resistance genes in bladder cancer.
Liu C; Wang XL; Shen EC; Wang BZ; Meng R; Cui Y; Wang WJ; Shao Q
Transl Androl Urol; 2022 Dec; 11(12):1715-1728. PubMed ID: 36632166
[TBL] [Abstract][Full Text] [Related]
27. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
Chen F; Wang Q; Zhou Y
BMC Cancer; 2021 Mar; 21(1):244. PubMed ID: 33685397
[TBL] [Abstract][Full Text] [Related]
28. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
Li R; Zhao W; Liang R; Jin C; Xiong H
Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
[No Abstract] [Full Text] [Related]
29. Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
Xing P; Jiang Z; Liu Y
BMC Cancer; 2022 Aug; 22(1):926. PubMed ID: 36030212
[TBL] [Abstract][Full Text] [Related]
30. Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer.
Yao Z; Zhang H; Zhang X; Zhang Z; Jie J; Xie K; Li F; Tan W
Front Genet; 2022; 13():923768. PubMed ID: 36147509
[TBL] [Abstract][Full Text] [Related]
31. A Prognostic Model for Predicting Tumor Mutation Burden and Tumor-Infiltrating Immune Cells in Bladder Urothelial Carcinoma.
Wang C; Chen S; Li S; Mi H
Front Genet; 2022; 13():708003. PubMed ID: 35251120
[TBL] [Abstract][Full Text] [Related]
32. TNF Family-Based Signature Predicts Prognosis, Tumor Microenvironment, and Molecular Subtypes in Bladder Carcinoma.
Li H; Liu S; Li C; Xiao Z; Hu J; Zhao C
Front Cell Dev Biol; 2021; 9():800967. PubMed ID: 35174161
[No Abstract] [Full Text] [Related]
33. Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer.
Sun J; Yue W; You J; Wei X; Huang Y; Ling Z; Hou J
Front Oncol; 2021; 11():730716. PubMed ID: 34557413
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
35. Deciphering the significance of anoikis in bladder cancer and systematic analysis of S100A7 as a potential therapeutic target.
Wang H; Liu J; Tang R; Hu J; Liu M; Wang J; Zhang J; Hou H
Eur J Med Res; 2024 Jan; 29(1):52. PubMed ID: 38217031
[TBL] [Abstract][Full Text] [Related]
36. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
37. Analysis of M2 macrophage-associated risk score signature in pancreatic cancer TME landscape and immunotherapy.
Yang D; Zhao F; Su Y; Zhou Y; Shen J; Zhao K; Ding Y
Front Mol Biosci; 2023; 10():1184708. PubMed ID: 37469705
[No Abstract] [Full Text] [Related]
38. Construction and experimental validation of a macrophage cell senescence-related gene signature to evaluate the prognosis, immunotherapeutic sensitivity, and chemotherapy response in bladder cancer.
Jiang Q; Zhou J; Chen Q; Huang Y; Yang C; Liu C
Funct Integr Genomics; 2023 Jul; 23(3):228. PubMed ID: 37423913
[TBL] [Abstract][Full Text] [Related]
39. Construction and validation of a macrophage polarization-related prognostic index to predict the overall survival in patients with early-stage triple-negative breast cancer.
Luo H; Hong R; Xu Y; Zheng Q; Xia W; Lu Q; Jiang K; Xu F; Chen M; Shi D; Deng W; Wang S
Gland Surg; 2023 Feb; 12(2):225-242. PubMed ID: 36915811
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
